Dentatorubral-pallidoluysian Atrophy Natural History and Biomarkers Study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 225
- 试验地点
- 3
- 主要终点
- Brain atrophy
研究概览
简要总结
DRPLA Natural History and Biomarkers Study (DRPLA NHBS) is a prospective observational study that will lay the foundation for clinical trials in DRPLA. The aims of this project are:
- To characterize the natural history of DRPLA in both juvenile- and adult-onset patients and study different modalities of biomarkers in this condition.
- To identify genetic factors and biomarkers that could predict disease progression.
- To provide a platform to support the design and conduct of clinical trials.
This study has three arms:
- Adult Participants: this arm of the study will require participants to be 16 years old or over to participate.
- Pediatric Participants: this arm of the study will require participants to be under 16 years old to participate.
- Remote Participants: patients that cannot or do not wish to travel to one of the study sites can participate in this arm of the study, irrespective of their age.
Participants will have an annual visit for three years (baseline visit and two follow-up visits, three visits in total). Subjects who complete the whole protocol will be assessed on two consecutive days to reduce patient burden.
This project will allow for a better understanding of DRPLA and its course, and therefore allow for future clinical trials on this condition to be more precisely and effectively conducted.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Brain atrophy
时间窗: 3 years
Brain MRI is used to measure atrophy. Atrophy is expected to be observed in DRPLA patients, and in particular in the brainstem, superior cerebellar peduncle, cerebellum and thalamus.
Neurofilament plasma concentration (NfL)
时间窗: 3 years
Blood and CSF samples will be measured for NfL, a brain-derived protein.
Scale for the assessment and rating of ataxia (SARA)
时间窗: 3 years
Progression of ataxia is measured using a validated ataxia scale, SARA. Scores range from 0 (no ataxia) to 40 (most severe ataxia).
次要结局
- Upper limb function test AIM-S(3 years)
- Clinical Assessment of Dysphagia in Neurodegeneration (CADN)(3 years)
- Inventory of non-ataxia signs (INAS)(3 years)
- Tau plasma concentration(3 years)
- Glial fibrillary acidic protein (GFAP) concentration(3 years)
- Ubiquitin carboxyterminal hydrolase L1 (UCH-L1) concentration(3 years)
- Redenlab DRPLA specific speech battery(3 years)
